Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma
A Phase II/III Randomized Study of R-MiniCHOP With or Without CC-486 (Oral Azacitidine) in Participants Age 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma, Grade IIIB Follicular Lymphoma, Transformed Lymphoma, and High-Grade B-Cell Lymphomas With MYC AND BCL2 and/or BCL6 Rearrangements
Sponsor: National Cancer Institute (NCI)
Suspended
End of Initial Phase of Multi-phase protocol
A observational or N/A phase clinical study on Ann Arbor Stage III Diffuse Large B-Cell Lymphoma and Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, this trial is suspended. The trial is conducted by National Cancer Institute (NCI) and has accumulated 53 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Study Description(click to expand)PRIMARY OBJECTIVES: I. To determine if the addition of CC-486 (oral azacitidine) to R-miniCHOP results in excess toxicity compared to R-miniCHOP alone that would preclude the combination from being studied further. (Safety run-in) II. To determine if the CC-486 + R-miniCHOP regimen should be tested further (Phase III) against the control R-miniCHOP alone based on progression-free survival (PFS). (Phase II component) III. To compare the overall survival (OS) between CC-486 + R-miniCHOP and R-miniCHOP alone. (Phase III component) SECONDARY OBJECTIVES: I. To assess the feasibility of delivering at least 4 cycles of CC-486 with R-miniCHOP in this population. II. To assess toxicity for CC-486 + R-miniCHOP and for R-miniCHOP. III. To compare complete response rates, as defined by Lugano 2014 classification, between CC-486 + R-miniCHOP and R-miniCHOP alone. INTEGRATED CORRELATIVE GERIATRIC ASSESSMENTS: I. To compare functioning as assessed by the S1918 Comprehensive Geriatric Assessment (S1918 CGA) between participants treated with CC-486 + R-miniCHOP versus R-miniCHOP alone. II. To evaluate if frailty status (fit/unfit versus \[vs\] frail/superfrail) as assessed by the FIL tool is associated with OS. III. To evaluate if frailty as measured by the FIL tool correlates with the summary frailty index as measured using components of the S1918...
PRIMARY OBJECTIVES:
I. To determine if the addition of CC-486 (oral azacitidine) to R-miniCHOP results in excess toxicity compared to R-miniCHOP alone that would preclude the combination from being studied further. (Safety run-in) II. To determine if the CC-486 + R-miniCHOP regimen should be tested further (Phase III) against the control R-miniCHOP alone based on progression-free survival (PFS). (Phase II component) III. To compare the overall survival (OS) between CC-486 + R-miniCHOP and R-miniCHOP alone. (Phase III component)
SECONDARY OBJECTIVES:
I. To assess the feasibility of delivering at least 4 cycles of CC-486 with R-miniCHOP in this population.
II. To assess toxicity for CC-486 + R-miniCHOP and for R-miniCHOP. III. To compare complete response rates, as defined by Lugano 2014 classification, between CC-486 + R-miniCHOP and R-miniCHOP alone.
INTEGRATED CORRELATIVE GERIATRIC ASSESSMENTS:
I. To compare functioning as assessed by the S1918 Comprehensive Geriatric Assessment (S1918 CGA) between participants treated with CC-486 + R-miniCHOP versus R-miniCHOP alone.
II. To evaluate if frailty status (fit/unfit versus \[vs\] frail/superfrail) as assessed by the FIL tool is associated with OS.
III. To evaluate if frailty as measured by the FIL tool correlates with the summary frailty index as measured using components of the S1918 CGA.
BANKING OBJECTIVE:
I. To bank specimens for future correlative studies.
OUTLINE:
Beginning 7 days prior to starting \[protocol treatment, all patients receive vincristine sulfate intravenously (IV) on day 1, and prednisone orally (PO) daily on days 1-7.
Patients are then randomized to 1 of 2 arms.
ARM I: Patients receive CC-486 PO for 7 days prior to cycle 1. Patients then receive CC-486 PO on days 8-21. Treatment repeats every 21 days for cycles 1-5 in the absence of disease progression or unacceptable toxicity. Patients also receive rituximab IV (or rituximab and hyaluronidase human subcutaneously \[SC\] for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for cycles 1-6 (6 cycles total) in the absence of disease progression or unacceptable toxicity. Patients undergo echocardiography (ECHO) or multigated acquisition scan (MUGA) at screening and undergo positron emission tomography (PET)-computed tomography (CT) and blood sample collection throughout the study.
ARM II: Patients receive rituximab IV (or rituximab and hyaluronidase human SC for cycles 2-6), cyclophosphamide IV, doxorubicin hydrochloride IV, and vincristine sulfate IV on day 1, and prednisone PO on days 1-5. Treatment repeats every 21 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo ECHO or MUGA at screening and undergo PET-CT and blood sample collection throughout the study.
After completion of study treatment, patients are followed up periodically until 5 years from the date of registration.
Status Flow
Change History
53 versions recorded-
Apr 14, 2026 — Present [daily]
Suspended
Phase: PHASE2/PHASE3 → None
-
Mar 2026 — Present [monthly]
Suspended PHASE2/PHASE3
-
Feb 2026 — Mar 2026 [monthly]
Suspended PHASE2/PHASE3
-
Nov 2025 — Feb 2026 [monthly]
Suspended PHASE2/PHASE3
-
Oct 2025 — Nov 2025 [monthly]
Suspended PHASE2/PHASE3
▶ Show 48 earlier versions
-
Sep 2025 — Oct 2025 [monthly]
Suspended PHASE2/PHASE3
-
Aug 2025 — Sep 2025 [monthly]
Suspended PHASE2/PHASE3
-
Jul 2025 — Aug 2025 [monthly]
Suspended PHASE2/PHASE3
-
May 2025 — Jul 2025 [monthly]
Suspended PHASE2/PHASE3
Status: Recruiting → Suspended
-
Apr 2025 — May 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Mar 2025 — Apr 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Jan 2025 — Feb 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Dec 2024 — Jan 2025 [monthly]
Recruiting PHASE2/PHASE3
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Oct 2024 — Nov 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Sep 2024 — Oct 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2/PHASE3
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2/PHASE3
Phase: PHASE2_PHASE3 → PHASE2/PHASE3
-
Jun 2024 — Jul 2024 [monthly]
Recruiting PHASE2_PHASE3
-
May 2024 — Jun 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2024 — May 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2024 — Apr 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2024 — Mar 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2024 — Feb 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2023 — Jan 2024 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2023 — Dec 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2023 — Nov 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Aug 2023 — Sep 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Jul 2023 — Aug 2023 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2023 — Jul 2023 [monthly]
Recruiting PHASE2_PHASE3
-
May 2023 — Jun 2023 [monthly]
Recruiting PHASE2_PHASE3
Status: Suspended → Recruiting
-
Apr 2023 — May 2023 [monthly]
Suspended PHASE2_PHASE3
-
Mar 2023 — Apr 2023 [monthly]
Suspended PHASE2_PHASE3
-
Feb 2023 — Mar 2023 [monthly]
Suspended PHASE2_PHASE3
-
Dec 2022 — Feb 2023 [monthly]
Suspended PHASE2_PHASE3
-
Nov 2022 — Dec 2022 [monthly]
Suspended PHASE2_PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Suspended PHASE2_PHASE3
Status: Recruiting → Suspended
-
Jul 2022 — Sep 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2022 — Jul 2022 [monthly]
Recruiting PHASE2_PHASE3
-
May 2022 — Jun 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Apr 2022 — May 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Feb 2022 — Mar 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2022 — Feb 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2021 — Jan 2022 [monthly]
Recruiting PHASE2_PHASE3
-
Nov 2021 — Dec 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Sep 2021 — Oct 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2_PHASE3
-
May 2021 — Jun 2021 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
Apr 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Eligibility Summary
This phase II/III trial compares the side effects and activity of oral azacitidine in combination with the standard drug therapy (reduced dose rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisone \[R-miniCHOP\]) versus R-miniCHOP alone in treating patients 75 years or older with newly diagnosed diffuse large B cell lymphoma. R-miniCHOP includes a monoclonal antibody (a type of protein), called rituximab, which attaches to the lymphoma cells and may help the immune system kill these cells. R-miniCHOP also includes prednisone which is an anti-inflammatory medication and a combination of 3 chemotherapy drugs, cyclophosphamide, doxorubicin, and vincristine. These 3 chemotherapy drugs, as well as oral azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Combining oral azacitidine with R-miniCHOP may shrink the cancer or extend the time without disease symptoms coming back or extend patient's survival when compared to R-miniCHOP alone.
Contact Information
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .